Incyte and Genmab Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer

What happened: Incyte ($INCY) and Genmab ($GMAB) announced a clinical trial collaboration to evaluate Incyte's KRAS G12D inhibitor INCB161734 with Genmab's petosemtamab and standard-of-care chemotherapy in first-line KRAS G12D-mutated metastatic colorectal cancer. Key numbers: Phase 1/2 study. Why it matters: Genmab will conduct the study and Incyte will co-fund it and supply INCB161734. Both executives framed the combination as exploring complementary mechanisms toward a potential new first-line treatment approach in an area of unmet need. Source: eodhd Market: -0.5% today ($2,640.00), +31.5% YTD — as of 07:45 UTC

Incyte ($INCY) and Genmab ($GMAB) announced a clinical trial collaboration to evaluate Incyte's KRAS G12D inhibitor INCB161734 with Genmab's petosemtamab and standard-of-care chemotherapy in first-line KRAS G12D-mutated metastatic colorectal cancer.

Genmab will conduct the study and Incyte will co-fund it and supply INCB161734. Both executives framed the combination as exploring complementary mechanisms toward a potential new first-line treatment approach in an area of unmet need. Source: eodhd Market: -0.5% today ($2,640.00), +31.5% YTD — as of 07:45 UTC